Cutting-edge Biotech news: Presented the old-fashioned way.
BioSpace
- Trump Administration Pulls CDC Nominee Dave Weldon at Last Minute
(5h)
- Houston’s Life Sciences Scene Continues Boosting Its Reputation
(6h)
- Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy
(6h)
- “Perfect Patient” Industry Burdens; Exits and Investment in Women’s Health
(6h)
- Amgen's Uplizna Deepens Response Against Myasthenia Gravis at 1 Year
(6h)
- J&J, Legend Pump $150M Into Manufacturing in Bid to Double Carvykti Production
(7h)
- Troubled drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
(7h)
- Troubled Drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
(7h)
- Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
(1d)
- Good Day for Gardasil as Merck Wins Safety Suit, Drops $1B for Manufacturing Push
(1d)
- Roche Makes Another Obesity Play With Potential $5.3B Amylin Pact With Zealand
(1d)
- Ionis Sends Polycythemia Vera Drug to Ono in Licensing Deal Worth Nearly $1B Biobucks
(1d)
- COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More
(1d)
- Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs
(1d)
- 16 Years And 3 Texas Two-Steps Later, J&J’s Talc Lawsuit Awaits Key Ruling
(1d)
- Viking Secures 1B Supply of Obesity Pill Candidate With $150M Prepayment Deal
(2d)
- Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug
(2d)
- The Shape of a Pandemic: Boom, Bust and Recover
(2d)
- Roche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy Unit
(2d)
- Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD
(2d)
Stat News*
- The sudden withdrawal of a CDC nominee and what went wrong with Covid policies
(23m)
- Study reveals how often medical device makers report safety incidents late to FDA
(4h)
- Trump’s picks to run FDA and NIH win approval from Senate’s health committee
(6h)
- A study on brains and a statement on driving
(6h)
- Pharmalittle: We’re reading about senators probing telehealth, Boston’s slumping biotech hub and more
(6h)
- White House pulls nomination of Dave Weldon as CDC director hours before hearing
(7h)
- In the Boston area, biotech’s hub, a slump is being acutely felt
(7h)
- Soleno Therapeutics’ ‘life-changing’ drug nears approval decision
(9h)
- Top addiction researcher Nora Volkow on NIH cuts, optimism and the limits of RFK Jr.’s 12-step experience
(11h)
- Biotech raising $35 million to take a second stab at cancer drug from Bert Vogelstein’s lab
(11h)
- Federal research instability risks postdoc careers, American leadership
(11h)
- HIV self-testing is easy, effective — and underutilized
(11h)
- Top addiction researcher Nora Volkow on NIH cuts, optimism, and the limits of RFK Jr.’s 12-step experience
(11h)
- CDC’s reported study on vaccines and autism could test RFK Jr.’s pledges to a key senator
(23h)
- Harvard Medical physicians sue over removal of articles mentioning ‘LGBTQ’ from government website
(1d)
- Telehealth platforms in senators’ crosshairs over relationship with Eli Lilly, Pfizer
(1d)
- Why health experts fear the West Texas measles outbreak may be much larger than reported
(1d)
- Food insecurity in early adulthood raises the risk of heart disease, long-term study shows
(1d)
- Should health care providers tell patients they are using AI?
(1d)
- Lilly CEO got a big payday (and an Olympics treat)
(1d)
Google News Biotech
- Bio-Tech Flavor Market Growth forecast 2034: valuation expected to reach $69.03 billion at a CAGR of 7.2% - Global Banking And Finance Review
(24m)
- George Church spinout GRObio explores strategic alternatives 6 months after Bayer-backed series B - Fierce Biotech
(2h)
- Salipro Biotech inks deal with Boehringer
(3h)
- Biotech Alert: Searches spiking for these stocks today - TipRanks
(4h)
- VUB to strengthen Brussels' position in biotech sector - The Brussels Times
(4h)
- Sotio takes up option on ADCs, Boehringer inks discovery pact - Fierce Biotech
(5h)
- Biotech startup Insilico has increased its value to $1 billion in financing - AK&M News
(6h)
- This biotech stock is a buy thanks to its cancer treatment pipeline, Citi says - CNBC
(6h)
- Houston’s Life Sciences Scene Continues Boosting Its Reputation - BioSpace
(6h)
- Sotio takes up option on ADCs, while Boehringer inks GPCR discovery pact - Fierce Biotech
(6h)
- PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer - TradingView
(6h)
- Immorta Bio Presents SenoVax™ Mediated Tumor Remission Data at International Biotechnology Conference - PR Newswire
(6h)
- Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More - Zacks Investment Research
(6h)
- Trinity Biotech rises after saying it will focus on CGM technology - TradingView
(7h)
- J&J, Legend Pump $150M Into Manufacturing in Bid to Double Carvykti Production - BioSpace
(7h)
- Boehringer Ingelheim Taps Salipro Biotech to Accelerate Pipeline Programs
(7h)
- Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to Accelerate Multiple Boehringer Ingelheim Pipeline Programs - The Manila Times
(7h)
- Boston Life Sciences, Biotech, Pharma, and Medical Facilities Conference Set for April 17, 2025 - India New England
(7h)
- ImmunoPrecise teases $10M ADC, bispecific collab with major biotech - Fierce Biotech
(7h)
- ImmunoPrecise teases $10M ADC collab with major biotech - Fierce Biotech
(7h)
* May require subscription